Skip to main content

Gloria Mª Fraga Rodriguez

Institutions of which they are part

Senior researcher
Kidney Physiopathology
Vall Hebron Institut de Recerca

Gloria Mª Fraga Rodriguez

Institutions of which they are part

Senior researcher
Kidney Physiopathology
Vall Hebron Institut de Recerca

Projects

Biomarcadores, dianas y soluciones terapéuticas para mejorar el cuidado de pacientes afectados de Hipomagnesemia Familiar con Hipercalciuria y Nefrocalcinosis (HFHNC).

IP: Gema Ariceta Iraola
Collaborators: Hector Rios Duro, Julieta Torchia Pruzzo, Gloria Mª Fraga Rodriguez
Funding agency: Instituto de Salud Carlos III
Funding: 202070
Reference: PI22/01946
Duration: 01/01/2023 - 30/06/2027

Papel del ClC-5 en la fibrosis renal. Identificación de posibles biomarcadores y dianas terapéuticas para la progresión de la enfermedad de Dent 1

IP: Gerard Cantero Recasens
Collaborators: Papel del ClC-5 en la fibrosis renal. Identificación de posibles biomarcadores y dianas terapéuticas para la progresión de la e, Andrea Casal Pardo, Hector Rios Duro, Julieta Torchia Pruzzo, Gloria Mª Fraga Rodriguez
Funding agency: Instituto de Salud Carlos III
Funding: 123420
Reference: PI22/00741
Duration: 01/01/2023 - 30/06/2027

Patologia Cel·lular

IP: Patologia Cel·lular
Collaborators: Gema Ariceta Iraola, Alejandro Cruz Gual, Gerard Cantero Recasens, David Lorente García, Marina Muñoz López, Mercedes López González, Hector Rios Duro, Patologia Cel·lular, Luis Augusto Castro Sáder, Gloria Mª Fraga Rodriguez, Julieta Torchia
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 01600
Duration: 01/01/2022 - 30/06/2025

Related news

The event, held at the VHIR Main Building, marked more than a decade of collaboration between the Institute and the HIPOFAM association and included a co-creation session to identify challenges and needs among patients and professionals.

The Oliver Wrong Research Award, granted by the Dent Disease Foundation, will fund a project combining kidney organoids and artificial intelligence to identify potential treatments for this rare kidney disease.

The team has discovered that a protein called SEC22B acts as a phenotype modifier and could be used as a potential urinary marker of the disease.

Related professionals

Cristina Gamez Cenzano

Cristina Gamez Cenzano

Senior researcher
Molecular Imaging and Therapy
Read more
Ana Belén Méndez Fernández

Ana Belén Méndez Fernández

Main researcher
Cardiovascular Diseases
Read more
Lucy Dougherty de Miguel

Lucy Dougherty de Miguel

Research technician
Pediatric Neurology
Read more
Mariona Juvé Torres

Mariona Juvé Torres

Research technician
Nephrology and kidney transplantation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.